American Century Companies Inc. Has $189.50 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

American Century Companies Inc. raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 16.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,051,517 shares of the biopharmaceutical company's stock after buying an additional 288,009 shares during the quarter. American Century Companies Inc. owned 0.16% of Gilead Sciences worth $189,499,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in GILD. HHM Wealth Advisors LLC lifted its stake in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership bought a new stake in Gilead Sciences in the fourth quarter valued at $28,000. Decker Retirement Planning Inc. acquired a new position in Gilead Sciences during the fourth quarter worth $29,000. Crews Bank & Trust bought a new position in shares of Gilead Sciences during the fourth quarter valued at $31,000. Finally, Stephens Consulting LLC boosted its stake in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 260 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the sale, the chief financial officer now directly owns 169,061 shares of the company's stock, valued at approximately $19,977,938.37. This represents a 9.59 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last three months, insiders sold 302,785 shares of company stock worth $30,503,250. 0.16% of the stock is currently owned by company insiders.

Remove Ads

Gilead Sciences Stock Up 1.7 %

GILD traded up $1.89 during trading on Thursday, hitting $111.16. The company had a trading volume of 6,382,732 shares, compared to its average volume of 6,810,437. The firm's 50-day moving average price is $104.69 and its 200 day moving average price is $94.46. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The company has a market capitalization of $138.43 billion, a PE ratio of 300.43, a PEG ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.84%. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's payout ratio is presently 854.05%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Piper Sandler lifted their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. BMO Capital Markets boosted their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a report on Wednesday, February 12th. Wells Fargo & Company raised their price target on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Royal Bank of Canada boosted their price objective on Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research note on Wednesday, February 12th. Finally, Cantor Fitzgerald restated a "neutral" rating and set a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $105.12.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.